- KRAS G12D INHIBITORS
-
The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
- -
-
Paragraph 0176
(2022/02/15)
-
- QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
-
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.
- -
-
Paragraph 183
(2022/01/12)
-
- TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
-
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer. (I)
- -
-
Page/Page column 246-248; 380; 381
(2021/07/17)
-
- KRAS G12D INHIBITORS
-
The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
- -
-
-
- PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS
-
The present invention is directed to inhibitors of Kirsten Rat sarcoma virus (KRAS), and more particularly to compounds of Formula (I), as well as compositions comprising Formula I and methods of using the compound of Formula I for the treatment or prevention of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS mutant G12C.
- -
-
Paragraph 0065
(2021/08/27)
-
- KRAS G12C INHIBITORS
-
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
- -
-
-